Publications by authors named "M Brawer"
Article Synopsis
- The clinical cell-cycle risk (CCR) score combines two established assessments to predict disease progression in prostate cancer patients and has been validated for men undergoing radiation therapy with or without hormonal treatment.
- In a study of 741 men with various risk levels of prostate cancer, the CCR score was found to be a significant predictor of metastatic risk, outperforming other score systems like NCCN and CAPRA.
- Findings showed that men with CCR scores below a specific threshold had a markedly lower risk of metastasis over ten years compared to those with higher scores, highlighting the score's clinical utility in guiding treatment decisions.
Introduction: The combined clinical cell-cycle risk (CCR) score is a validated model that combines the cell-cycle progression (CCP) score with the University of California San Francisco Cancer of the Prostate Risk Assessment (CAPRA) score. This score determines the risk of progressive disease for men with prostate cancer. Here, we further validate the prognostic ability of the CCR score and evaluate its ability to help determine which patients may safely forgo multimodality therapy.
View Article and Find Full Text PDFBackground: Very long-term mortality in men with early prostate cancer treated with surgery versus observation is uncertain.
Objective: To determine long-term effects of surgery versus observation on all-cause mortality for men with early prostate cancer.
Design, Setting, And Participants: This study evaluated long-term follow-up of a randomized trial conducted at the US Department of Veterans Affairs and National Cancer Institute sites.